



Erlotinib (Tarceva®)

Roche Products Ltd

August 2008

Appraisal notice to NHS Wales

Erlotinib (Tarceva®) in combination with gemcitabine has not been endorsed for use within NHS Wales for the treatment of patients with metastatic pancreatic cancer.

The holder of the marketing authorisation has not made a submission to AWMSG for the appraisal of erlotinib (Tarceva®) in the above indication. As a result, AWMSG cannot advise the Minister for Health and Social Services whether this medicine should be available for use within NHS Wales.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

AWMSG takes into account the NICE future work programme when considering whether a product will be appraised. AWMSG does not normally consider appraising a product if NICE intends to publish their final appraisal of the same product within a 18 month period from receipt of Form B. i.e. approx 12 months from the projected AWMSG appraisal date. AWMSG advice is interim to that of NICE, should NICE subsequently publish guidance.

This notice is provided for information to NHS Wales. In the absence of guidance issued by NICE or AWMSG, clinicians should continue to exercise their clinical judgement when providing care for an individual patient. This should be in consultation with the patient and/or guardian or carer, based on the best available evidence.